Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
0.423
+0.011 (2.74%)
At close: Feb 3, 2025, 4:00 PM
0.410
-0.013 (-3.17%)
After-hours: Feb 3, 2025, 7:50 PM EST
Scilex Holding Company Employees
Scilex Holding Company had 105 employees as of December 31, 2023. The number of employees increased by 15 or 16.67% compared to the previous year.
Employees
105
Change (1Y)
15
Growth (1Y)
16.67%
Revenue / Employee
$525,257
Profits / Employee
-$835,686
Market Cap
77.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 105 | 15 | 16.67% |
| Dec 31, 2022 | 90 | 14 | 18.42% |
| Dec 31, 2021 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
SCLX News
- 3 days ago - Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 18 days ago - Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - GlobeNewsWire
- 5 weeks ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025 - GlobeNewsWire
- 7 weeks ago - Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - GlobeNewsWire